Top of the morning to you, and a fine one it is. Clear blue skies and pleasant breezes are enveloping the Pharmalot campus, where the official mascots are foraging for noshes and keeping strangers at bay. As for us, we are engaged in the usual rituals, starting with firing up the coffee kettle — our choice today is blueberry cobbler — and hunting for items of interest. On that note, please enjoy the tidbits compiled below. We hope you have a smashing day and conquer the world. And as always, please do keep in touch. …
An Eli Lilly investigational obesity pill largely helped patients maintain their weight loss after they switched from the potent injectable treatments Wegovy and Zepbound, results that could widen the appeal of the medicine, STAT writes. Doctors and investors have had high hopes for orforglipron, since it would be the first small molecule GLP-1 drug on the market. The pill is expected to be easier to manufacture and distribute than the injections. Observers were disappointed, though, when orforglipron was not as effective as anticipated in one of its Phase 3 trials. The latest data suggest that even though it may not lead to as much weight loss as Wegovy or Zepbound, it could be useful for patients who want to transition off the injections, which can be inconvenient to administer.
More than three dozen state attorneys general are urging Meta to better enforce its policies to thwart a “surge of misleading” pharmaceutical and wellness ads for weight loss drugs on Instagram and Facebook, STAT notes. And the state officials also want the company to take additional measures to prevent artificial intelligence-generated content in the ads. In a letter to Meta, they cite company policies indicating pharmaceutical advertisers are supposed to share information about the medical effectiveness and affordability of their medicines and target only adults. The state officials also cited policies that say health and wellness ads should not push a “perfect” body type or provide side-by-side comparisons.
Continue to STAT+ to read the full story…
STAT Pharma: The science and business of new drug development
Leave a Reply